First Efficacy Results From the Turandot Phase III Trial Comparing Two Bevacizumab (BEV)-Containing Regimens as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MBC)
作者
Christoph Zielinski,István Láng,Moshe Inbar,Zsuzsanna Kahán,Richard Greil,S. Beslija,Salomon M. Stemmer,Bella Kaufman,Zanete Zvirbule,Guenther G. Steger,Bohuslav Melichar,Tadeusz Pieńkowski,Daniela Sîrbu,Luboš Petruželka,Alexandru Eniu,Bella Nisenbaum,Magdolna Dank,Rodica Maricela Anghel,Diethelm Messinger,Thomas Brodowicz
出处
期刊：Annals of Oncology [Elsevier BV] 日期：2012-09-01卷期号：23: ix116-ix116被引量：7
PDF的下载单位、IP信息已删除
(2025-6-4)
张欢馨
Criminology34
GingerF
cdercder
学术孤儿
实验室
ansteel
lili
OK
可靠铸海
迪西
梁静茹给我的勇气
aubusson
渡人舟
东方元语
aajhajkahna
YifanWang
斯文的白玉
Nexus
初景
皖公网安备34019202002308
